Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
messenger RNA cancer neoantigen vaccine
- Development stage
- Preclinical
- Lead developer
- Grid Biosciences
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular, Subcutaneous, Intravenous, Intranasal, Inhalation, Intranodal, Intrasplenic, Intratumoral, Transdermal
01
Overview
The messenger RNA cancer neoantigen vaccine is a personalized therapeutic vaccine platform developed by Grid Biosciences. This program utilizes the Grid AI Lab, a machine learning-based platform, to identify and optimize tumor-specific neoantigens unique to each patient. The vaccine consists of mRNA encoding these personalized neoantigens, which is designed to stimulate the patient's immune system to mount a specific anti-tumor response. It is currently in the development and platform stage, intended for use as a personalized immunotherapy across various cancer types.
- Other names
- personalized mRNA neoantigen vaccinemRNA Cancer Neoantigen Vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on messenger RNA cancer neoantigen vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on messenger RNA cancer neoantigen vaccine.